Words for clinical notes
Search 5,131 terms by clinical wording, everyday description, or note example.
| Word | Plain-English search cue | Original note example | SOAP section | Writing task |
|---|---|---|---|---|
fosphenytoin | prodrug converted to phenytoin, relevant to level timing and analyte identity | The administration record lists fosphenytoin and the laboratory measured phenytoin. | Objective | Drug levels - named analytes and exposure reports |
valproate | antiseizure and mood-stabilizing drug measured as total or free | The report identifies free valproate and lists the corresponding total concentration. | Objective | Drug levels - named analytes and exposure reports |
carbamazepine | antiseizure medicine with a separately measurable active epoxide metabolite | The carbamazepine and epoxide measurements appear on separate lines. | Objective | Drug levels - named analytes and exposure reports |
phenobarbital | barbiturate whose blood concentration may be monitored | The phenobarbital sample time is recorded after the most recent administration. | Objective | Drug levels - named analytes and exposure reports |
primidone | antiseizure medicine assessed separately from its phenobarbital metabolite | The laboratory reports both primidone and phenobarbital. | Objective | Drug levels - named analytes and exposure reports |
lamotrigine | antiseizure medicine for which a concentration may be compared with an individual baseline | The lamotrigine result is listed with the patient's earlier stable value. | Objective | Drug levels - named analytes and exposure reports |
levetiracetam | antiseizure medicine measurable in serum or plasma under an appropriate assay | The levetiracetam concentration was collected at a documented interval after the dose. | Objective | Drug levels - named analytes and exposure reports |
oxcarbazepine | antiseizure agent commonly monitored through its active monohydroxy metabolite | The order names oxcarbazepine and the report identifies its measured metabolite. | Objective | Drug levels - named analytes and exposure reports |
topiramate | antiseizure medicine with a measurable blood concentration | The outside topiramate report includes the collection date and assay units. | Objective | Drug levels - named analytes and exposure reports |
zonisamide | antiseizure medicine measurable by a drug-specific assay | The zonisamide specimen followed the dose change documented in the log. | Objective | Drug levels - named analytes and exposure reports |
theophylline | methylxanthine with formulation- and timing-dependent level interpretation | The theophylline level is filed with the extended-release product and dose time. | Objective | Drug levels - named analytes and exposure reports |
tacrolimus | transplant immunosuppressant typically monitored using whole-blood troughs | The tacrolimus result was measured in whole blood before the morning dose. | Objective | Drug levels - named analytes and exposure reports |
cyclosporine | immunosuppressant monitored using a specified timed sampling strategy | The cyclosporine report specifies whether the order was for a predose or two-hour sample. | Objective | Drug levels - named analytes and exposure reports |
sirolimus | mTOR inhibitor monitored using whole-blood concentrations in specified settings | The sirolimus report states whole blood and the collection time. | Objective | Drug levels - named analytes and exposure reports |
everolimus | mTOR inhibitor with indication-specific monitoring considerations | The everolimus trough is documented with the transplant team's stated target. | Objective | Drug levels - named analytes and exposure reports |
mycophenolic acid | active compound measured in certain mycophenolate exposure assessments | The mycophenolic acid report distinguishes the parent analyte from its glucuronide metabolite. | Objective | Drug levels - named analytes and exposure reports |
methotrexate | antimetabolite with protocol-timed levels in high-dose treatment | The methotrexate result is identified by hours from the protocol-defined infusion start. | Objective | Drug levels - named analytes and exposure reports |
busulfan | alkylating agent with protocol-specific pharmacokinetic sampling | Each busulfan sample is linked to the actual infusion record. | Objective | Drug levels - named analytes and exposure reports |
voriconazole | azole antifungal with selected use of trough monitoring | The voriconazole concentration is labeled with dose route and collection time. | Objective | Drug levels - named analytes and exposure reports |
posaconazole | azole antifungal whose formulation and timing matter for concentration review | The posaconazole report is filed with the formulation recorded in pharmacy history. | Objective | Drug levels - named analytes and exposure reports |
itraconazole | azole antifungal for which drug and active metabolite may be reported | The itraconazole and hydroxyitraconazole results are reported individually. | Objective | Drug levels - named analytes and exposure reports |
flucytosine | antifungal monitored using drug- and protocol-specific sampling | The flucytosine sample is documented with its exact postdose interval. | Objective | Drug levels - named analytes and exposure reports |
clozapine | antipsychotic whose concentration may be reported with its metabolite | The laboratory reports clozapine and norclozapine as separate analytes. | Objective | Drug levels - named analytes and exposure reports |
norclozapine | clozapine metabolite measured in some monitoring panels | The norclozapine result is listed with its own units. | Objective | Drug levels - named analytes and exposure reports |
nortriptyline | tricyclic antidepressant measurable in blood | The nortriptyline report gives the specimen time relative to the last dose. | Objective | Drug levels - named analytes and exposure reports |